ZERBAXA Drug Patent Profile

Which patents cover Zerbaxa, and when can generic versions of Zerbaxa launch?

Zerbaxa is a drug marketed by Cubist Pharms Llc and is included in one NDA. There are twelve patents protecting this drug.

This drug has one hundred and seventeen patent family members in thirty-eight countries.

The generic ingredient in ZERBAXA is ceftolozane sulfate; tazobactam sodium. One supplier is listed for this compound. Additional details are available on the ceftolozane sulfate; tazobactam sodium profile page.

DrugPatentWatch^® Generic Entry Outlook for Zerbaxa

Zerbaxa was eligible for patent challenges on December 19, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 14, 2035. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ZERBAXA

International Patents:	117
US Patents:	12
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	6
Drug Prices:	Drug price information for ZERBAXA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZERBAXA
What excipients (inactive ingredients) are in ZERBAXA?	ZERBAXA excipients list
DailyMed Link:	ZERBAXA at DailyMed

See drug prices for ZERBAXA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ZERBAXA

Constraining patent/regulatory exclusivity:

10,125,149

NDA:

206829

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ZERBAXA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Hamad Medical Corporation	Phase 4
University Hospital, Toulouse	Phase 3
Royal Brisbane and Women's Hospital	Phase 1/Phase 2

See all ZERBAXA clinical trials

Pharmacology for ZERBAXA

Drug Class	Cephalosporin Antibacterial beta Lactamase Inhibitor
Mechanism of Action	beta Lactamase Inhibitors

US Patents and Regulatory Information for ZERBAXA

ZERBAXA is protected by twenty-six US patents.

This potential generic entry date is based on patent 10,125,149.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cubist Pharms Llc	ZERBAXA	ceftolozane sulfate; tazobactam sodium	POWDER;INTRAVENOUS	206829-001	Dec 19, 2014		RX	Yes	Yes	7,129,232		Y	Y
Cubist Pharms Llc	ZERBAXA	ceftolozane sulfate; tazobactam sodium	POWDER;INTRAVENOUS	206829-001	Dec 19, 2014		RX	Yes	Yes	8,906,898		Y	Y
Cubist Pharms Llc	ZERBAXA	ceftolozane sulfate; tazobactam sodium	POWDER;INTRAVENOUS	206829-001	Dec 19, 2014		RX	Yes	Yes	10,376,496
Cubist Pharms Llc	ZERBAXA	ceftolozane sulfate; tazobactam sodium	POWDER;INTRAVENOUS	206829-001	Dec 19, 2014		RX	Yes	Yes	9,724,353
Cubist Pharms Llc	ZERBAXA	ceftolozane sulfate; tazobactam sodium	POWDER;INTRAVENOUS	206829-001	Dec 19, 2014		RX	Yes	Yes	10,125,149		Y
Cubist Pharms Llc	ZERBAXA	ceftolozane sulfate; tazobactam sodium	POWDER;INTRAVENOUS	206829-001	Dec 19, 2014		RX	Yes	Yes	8,968,753

International Patents for ZERBAXA

When does loss-of-exclusivity occur for ZERBAXA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

China

European Patent Office

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZERBAXA around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2848012
China	103945842
Denmark	3616695
Eurasian Patent Organization	028342
Eurasian Patent Organization	201490590
European Patent Office	2753326

Supplementary Protection Certificates for ZERBAXA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1556389	CA 2016 00004	Denmark		PRODUCT NAME: CEFTOLOZAN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, SAERLIGT ET SVOVLSYRESALT; REG. NO/DATE: EU/1/15/1032/001 20150922
1556389	CR 2016 00004	Denmark		PRODUCT NAME: CEFTOLOZAN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, SAERLIGT ET SVOVLSYRESALT; REG. NO/DATE: EU/1/15/1032/001 20150922
1556389	92943	Luxembourg		PRODUCT NAME: CEFTOLOZANE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, EN PARTICULIER UN SEL D'ACIDE SULFURIQUE (ZERBAXA); FIRST REGISTRATION: 20150922
1556389	300793	Netherlands		PRODUCT NAME: CEFTOLOZAAN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN IN HET BIJZONDER EEN ZWAVELZUURZOUT; REGISTRATION NO/DATE: EU/1/15/1032 20150922
1556389	16C0004	France		PRODUCT NAME: CEFTOLOZANE,EVENTUELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,PLUS PARTICULIEREMENT UN SEL D'ACIDE SULFURIQUE; REGISTRATION NO/DATE: EU/1/15/1032 20150922
1556389	122015000113	Germany		PRODUCT NAME: CEFTOLOZAN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON, INSBESONDERE EIN SCHWEFELSAEURESALZ; REGISTRATION NO/DATE: EU/1/15/1032/001 20150918

Last updated: June 4, 2026

ZERBAXA (ceftolozane and tazobactam) market dynamics and financial trajectory (US and key ex-US segments)

ZERBAXA (ceftolozane/tazobactam) remains a niche, high-cost hospital antibiotic tied to specific MDR Gram-negative and complicated intra-abdominal infection (cIAI) and complicated urinary tract infection (cUTI) prescribing pathways. In the US, revenue trajectory is driven by (1) competitive pressure from other beta-lactam/beta-lactamase inhibitor (BL/BLI) and cephalosporin classes, (2) formulary and IDSA-driven stewardship dynamics, and (3) payer containment focused on benchmarked per-course pricing for inpatient use. The commercial picture is structurally “volume constrained” by its narrower clinical pull compared with broader-spectrum products, while pricing is influenced by negotiated contracts and substitution within hospital antibiotic formularies.

Bottom line: ZERBAXA’s market performance is dominated by inpatient acuity, hospital formulary penetration, and episode-of-care economics rather than outpatient durability. Financial trajectory is best characterized as late-cycle stabilization with episodic growth tied to MDR infection management and procurement cycles, offset by generic or biosimilar substitution risk being low for this branded parenteral product and by therapeutic switching within the same stewardship category.

---

What market dynamics drive ZERBAXA sales for ceftolozane/tazobactam?

ZerbaXa’s commercial demand tracks the incidence and treatment selection for MDR Gram-negative infections in hospitalized patients, especially where clinicians use BL/BLI agents with activity against resistant Enterobacterales and certain Pseudomonas aeruginosa phenotypes.

How do stewardship, formularies, and ID decision support shape uptake?

• Stewardship gatekeeping: ID committees often limit BL/BLI use to guideline-concordant settings, requiring susceptibility context or prior therapy failure.
• Restricted formulary placement: Many hospitals keep ceftolozane/tazobactam behind prior authorization or “step therapy” rules for complicated infections.
• Pathogen susceptibility and antibiogram effects: Local antibiograms affect prescribing, with lower use when Pseudomonas susceptibility shifts against agent activity.
• Protocolized pathways for cUTI/cIAI: Adoption is highest where institutions embed ZERBAXA into infection order sets for specific risk profiles (eg, high MDR risk).

Where does ZERBAXA compete most directly?

Primary substitution categories in US hospital formularies include:

• Other BL/BLI antibiotics (coverage-oriented switching)
• Carbapenems for broad resistance coverage (often constrained by stewardship to reserve use)
• Cephalosporins and other anti-pseudomonal agents depending on local susceptibility patterns
• Combination therapies in severe sepsis pathways (where ZERBAXA may lose if clinicians prefer carbapenem + adjunct strategies)

Featured-snippet answer: ZERBAXA’s uptake is controlled by hospital formulary controls, local resistance patterns, and substitution among inpatient BL/BLI and reserve agents.

---

What is ZERBAXA’s revenue trajectory and financial trajectory by product cycle?

ZERBAXA’s financial trajectory follows a typical specialty hospital antibiotic curve:

1. Launch and label expansion phase: Uptake increases as clinical familiarity grows and contracting spreads beyond early adopter centers.
2. Maturing penetration phase: Growth becomes episodic and tied to MDR case mix, seasonal hospitalization volume, and annual procurement.
3. Late-cycle pressure phase: Share erosion occurs when competing agents gain formulary status or when stewardship protocols shift.

Key financial drivers that change quarter-to-quarter

• Unit sales vs. average selling price (ASP): Hospital contracting tends to reduce ASP while volumes remain relatively stable in restricted markets.
• Seasonality and admission mix: cUTI/cIAI-related admissions vary by quarter with hospital census shifts.
• Payer contract renewals: Multi-quarter contract timing can produce step changes in reported net sales.
• Inventory and wholesaler purchasing: Antibiotics can show lumpiness around procurement cycles.

What metrics investors and licensors typically track

• Net sales trend (YoY) and gross-to-net conversion, driven by rebates and chargebacks
• Hospital account expansion metrics and proportion of usage under restricted criteria
• Competitor formulary outcomes (systemwide switches)
• Share vs. comparator class growth rates (BL/BLI market)

---

How does ZERBAXA compare with competing antibiotics in market share and pricing power?

ZERBAXA operates in an intensely negotiated inpatient segment where “premium pricing” is constrained by:

• contract benchmarks,
• bundled hospital purchasing agreements,
• and stewardship-driven justification requirements.

Competitive set and positioning logic

Ceftolozane/tazobactam is positioned on:

• anti-pseudomonal activity in appropriate microbiology contexts,
• Gram-negative MDR coverage,
• and reduced need for broader reserve agents when resistance profiles allow.

Competing products tend to compete on:

• broader label breadth or perceived pathogen coverage,
• pricing and tender outcomes,
• and formulary relationships.

Commercial implication: ZERBAXA’s pricing power tends to be narrower than broad-spectrum agents and is most resilient when hospitals need a specific activity profile tied to antibiograms.

---

What patent estate and exclusivity structure supports ZERBAXA’s long-run commercial economics?

ZERBAXA is a branded, small-molecule parenteral product with exclusivity that affects near-term generic entry risk. The commercial economics remain anchored to continuing legal exclusivity and the absence of approved generic equivalents in the relevant US market segments.

How exclusivity typically maps to ZERBAXA’s sales durability

• Composition and method-of-use protections sustain branded pricing until challenged and adjudicated.
• Formulation/process claims can complicate straightforward generic equivalence depending on claim scope and process-specific steps.
• Regulatory exclusivity does not prevent biosimilar substitution since this is a chemically synthesized drug, but it does matter for 505(b)(2) route competition timing.

Featured-snippet answer: ZERBAXA’s long-run pricing sustainability is tied to patent and regulatory exclusivity preventing simple generic launch and preserving inpatient contracting leverage.

---

What is the Orange Book status of ZERBAXA and what does it imply for generic entry risk?

Generic entry risk depends on:

• the number and remaining term of Orange Book-listed patents,
• and whether any Paragraph IV certifications are filed and resolved.

Generic entry timeline mechanics

• If challenged, outcomes depend on claim scope, infringement findings, and settlement structures.
• If not challenged, entry timing is shaped by final expiration of the last listed patent.
• A late patent can delay first generic approval even if earlier patents expire.

Market implication: Even when clinical substitution exists, legal barriers can prevent lower-priced alternatives from reaching formularies.

---

When does ZERBAXA lose exclusivity and what are the plausible launch scenarios?

Late-cycle ZERBAXA financial trajectory depends on whether exclusivity ends with:

• (1) no litigation and a clean generic launch date,
• (2) partial settlements that delay entry,
• or (3) prolonged Paragraph IV litigation that pushes generic availability out.

Launch scenarios that affect financial trajectory

• Scenario A: Clean exclusivity end
  Immediate generic entry leads to net sales compression quickly after launch.
• Scenario B: Settlement delay
  Branded revenue persists longer while generic approval or launch is delayed.
• Scenario C: Invalidation or early carve-outs
  Some competitors enter earlier, causing uneven share loss by geography and contracting class.

Featured-snippet answer: ZERBAXA’s late-cycle sales stability is highly sensitive to the “last patent to expire” and the litigation posture around Orange Book-listed claims.

---

How does Paragraph IV litigation risk affect ZERBAXA’s near-term market stability?

Paragraph IV events can cause:

• pre-launch contracting renegotiation,
• customers shifting to alternative agents,
• and stockpiling or inventory pull-forward ahead of generic availability.

Typical financial effects

• Margin pressure near potential entry windows due to pricing concessions
• Volume drift to competitors with earlier formulary status
• Increased promotional or contracting intensity to defend share

Commercial implication: even without an approved generic, market expectations around litigation timing can alter hospital prescribing patterns.

---

What regulatory status factors most affect ZERBAXA prescribing volume in hospitals?

ZERBAXA is administered in inpatient settings and depends on:

• formulary inclusion in infection pathways,
• clinician familiarity and ID consultant alignment,
• and competitive comparators’ availability.

FDA pathway and labeling constraints

• Indication scope for cUTI and cIAI shapes patient selection and reduces off-label demand relative to broadly labeled antibiotics.
• Safety profile and renal dosing guidance affect prescribing in ICU and renal impairment populations.

Featured-snippet answer: ZERBAXA volume is strongly governed by label-concordant inpatient use tied to cUTI/cIAI risk stratification and resistance context.

---

Which company commercializes ZERBAXA and how does contracting structure influence financial trajectory?

Brand antibiotics typically monetize through:

• large hospital contracting,
• group purchasing organization (GPO) tender cycles,
• and ID center influence on restricted agent selection.

Contracting dynamics that drive net sales

• GPO alignment: Accounts aligned to a specific BL/BLI class may shift to the lowest bid that still meets antibiogram needs.
• Contract floors and rebates: ASP declines as rebate intensity increases during share defense.
• Systemwide formulary decisions: Large health systems can shift usage quickly if protocol committees adopt an alternative.

Market implication: net sales depend more on contract renewals and systemwide uptake than on incremental patient volume alone.

---

What is the financial exposure to ZERBAXA from biosimilar or generic substitution risk?

Because ZERBAXA is a chemical drug, biosimilar risk is not applicable. Exposure is primarily:

• generic entry and 505(b)(2) competitive substitution in the same indications and route,
• and switching among already-approved branded competitors.

Why substitution is not purely “clinical”

Hospitals tend to resist switching until:

• a competitor becomes preferred in stewardship pathways,
• or a lower-cost alternative is contractually mandated.

Featured-snippet answer: ZERBAXA is exposed to pricing compression from generics only at legal/regulatory entry, with interim pressure from competitive branded contracting and reserve stewardship shifts.

---

Key Takeaways

• ZERBAXA demand is inpatient-episode driven, controlled by MDR Gram-negative and pseudomonal risk selection, and constrained by restricted formulary/stewardship protocols.
• Financial trajectory reflects contracting cycles and ASP compression risk typical of hospital antibiotics, with volume stability when microbiology supports use.
• Long-term economics hinge on remaining Orange Book patent coverage and litigation posture that can delay or accelerate generic availability.
• Competitive pressure is largely within BL/BLI and reserve-agent decision frameworks, not in outpatient expansion.

---

FAQs

1. How do hospital antibiograms change ceftolozane/tazobactam utilization for cUTI?
2. What procurement mechanisms (GPO and system contracts) most affect ZERBAXA net price?
3. How do stewardship restrictions alter ZERBAXA’s forecasted volume across ICU vs non-ICU wards?
4. What financial impact do Paragraph IV filings typically have on branded hospital antibiotic sales before generic launch?
5. Which comparator BL/BLI agents most often replace ZERBAXA in cIAI formulary switches?

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (Ceftolozane; Tazobactam). U.S. Food and Drug Administration.
2. FDA. Drug Approval Reports and Labeling for ZERBAXA (ceftolozane and tazobactam). U.S. Food and Drug Administration.
3. IDSA. Clinical practice guidance for the management of complicated urinary tract infections and intra-abdominal infections. Infectious Diseases Society of America.
4. Bloomberg. (Product and company financial coverage for specialty hospital antibiotics). Bloomberg.